Hematologic Malignancies Program

UMGCC Participation at the 52nd ASH Annual Meeting

The American Society of Hematology (ASH) will hold its 52nd ASH Annual Meeting and Exposition from December 4-7, 2010 at the Orange County Convention Center in Orlando, Florida. Presentations delivered during this conference will present the most recent advances in hematology research, providing physicians and researchers throughout the world the opportunity to see what advancements are currently being made in the field. Below is a list of ASH presentations that will be delivered by members of the UMGCC faculty.

UMGCC Research Presentations

Inhibition of the Serine/Threonine Kinase Pim-1 Has Anti-Proliferative Effects In Acute Myeloid Leukemia (AML) and Sensitizes Multidrug Resistant Cells to Chemotherapy.

Karthika Natarajan, PhD, Mehmet Burcu, BS and Maria R. Baer, MD

Activation of a Novel Palmitoyltransferase through a t(6;14) Translocation In T/Myeloid Biphenotypic Leukemia and Subsets of Acute Myeloid Leukemia.

Yi Ning, PhD, Lei Yu, MD, Jocelyn Reader, PhD, Ching Chen, MD, Xianfeng Frank Zhao, MD, Jung Sook Ha, PhD, Charles Lee, PhD, Teresa York, MD, Ivana Gojo, MD and Maria R. Baer, MD

Phase II Study of the Cyclin-Dependent Kinase (CDK) Inhibitor Dinaciclib (SCH 727965) In Patients with Advanced Acute Leukemias.

Ivana Gojo, MD, Alison Walker, MD, Maureen Cooper, MD, Eric J. Feldman, MD, Swaminathan Padmanabhan, MBBS, MS, Maria R. Baer, MD, Jennifer Poon, PharmD, Karen Small, BSN, Da Zhang, MS, Mariola Sadowska, PhD and Rajat Bannerji, MD, PhD

Single Agent Activity of the Cyclin-Dependent Kinase (CDK) Inhibitor Dinaciclib (SCH 727965) In Acute Myeloid and Lymphoid Leukemia Cells.

Mariola Sadowska, PhD, Nidal Muvarak, BS, Rena G. Lapidus, PhD, Edward A. Sausville, MD, PhD, Rajat Bannerji, MD, PhD and Ivana Gojo, MD

Tertiary Center Referral Patterns for Myelodysplastic Syndrome (MDS) Patients Are Suggestive of Age and Race Disparities.

Dan P. Zandberg, MD, Jason Bierenbaum, MD, Ivana Gojo, MD, Michael L. Tidwell, CRNP, Yi Ning, PhD, Xianfeng Frank Zhao, MD, PhD, Amy J. Davidoff, MS, PhD and Maria R. Baer, MD

Presentation, Treatment, and Outcome for Twenty Consecutive Patients with Human Immunodeficiency Virus (HIV) Associated Thrombotic Microangiopathies (TMA).

Michael W. Evans, MD, MPH, Victoria S. Giffi, MD, Ann Zimrin, MD and John R. Hess, MD, MPH

The Dark Side of NRF2: Upregulation of NRF2 as a Mechanism for Resistance to Imatinib In CML.

Dipika Gemani, MS, Lisa A. Tobin, Anju Singh, MD, MPH, Maria R. Baer, MD, Shyam Biswal, PhD, MS and Feyruz Rassool, PhD

Spleen Status and Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation (HCT).

Gorgun Akpek, MD, MHS, Marcelo C. Pasquini, MD, MS, Manza-A Agovi, MPH, Brent Logan, PhD, Kenneth R. Cooke, MD, Richard T. Maziarz, MD, Vikas Gupta, MD, MRCP, FRCPath, Hillard M. Lazarus, MD, FACP, Gregory A. Hale, MD, David I. Marks, MBBS, PHD, Dipnarine Maharaj, MD, Uday Popat, MD, Matthew Carabasi, MD, Martin Bornhaeuser, Brian J. Bolwell, MD, Olle Ringden, MD, Karen K. Ballen, MD, J. Douglas Rizzo, MD, MS, Philip L. McCarthy, MD and Vincent T. Ho, MD

Access to Care, Race and Education Are Key Determinants of Erythropoietin Stimulating Agent (ESA) Use In Myelodysplastic Syndromes (MDS).

Amy J. Davidoff, PhD, MS, Sheila Weiss Smith, PhD, Maria R. Baer, MD, Xuehua Ke, MA, Jason M. Bierenbaum, MD, Franklin Hendrick, BS, Diane L. McNally, BSPharm, MS and Steven D. Gore, MD

The Mir-23a~Mir-27a~Mir-24 Cluster Acts as a Tumor Suppressor In Leukemias by Post-Transcriptional Regulation of 14-3-3 Proteins.

Kara A. Scheibner, PhD, Brie Teaboldt, Mary Claire Hauer and Curt I. Civin, MD

UMGCC Clinical Trial Participation

Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (MM).

Seema B. Singhal, MD, David Samuel diCapua Siegel, MD, PhD, Thomas Martin, MD, Ravi Vij, MBBS, MD, Michael Wang, MD, Andrzej J. Jakubowiak, MD, PhD, Sagar Lonial, MD, Vishal Kukreti, MD, FRCPC, Jeffrey A. Zonder, MD, Alvin F. Wong, PharmD, Leanne McCulloch, Michael Kauffman, MD, PhD, Ashraf Z. Badros, MD, Ruben Niesvizky, MD, Robert Z. Orlowski, MD, PhD, A. Keith Stewart, MB, ChB and Sundar Jagannath, MD

A Phase I Study of PD 0332991: Complete CDK4/6 Inhibition and Tumor Response In Sequential Combination with Bortezomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma.

Ruben Niesvizky, MD, Suzanne Lentzsch, MD, PhD, Ashraf Z. Badros, MD, Asher A. Chanan-Khan, MD, Seema B. Singhal, MD, Jeffrey A. Zonder, MD, Ravi Vij, MBBS, MD, Xiangao Huang, PhD, Maurizio DiLiberto, PhD, Rachel Courtney, PhD, M. Naveed Shaik, PhD, Sindy T. Kim, BS, Sophia Randolph, MD, PhD, Scott A Ely, MD, MPH and Selina Chen-Kiang, PhD

Challenges for Conducting Clinical Trials Evaluating Maintenance Chemotherapy In Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study.

William Blum, MD, Kate Donohue, PhD, Guido Marcucci, MD, Daniel J DeAngelo, MD, PhD, Geoffrey L. Uy, MD, Bayard L. Powell, MD, Wendy Stock, MD, Maria R. Baer, MD, Jonathan E. Kolitz, MD, Meir Wetzler, MD, Eva Hoke, Barry K. Moser, PhD and Richard A Larson, MD

Subcutaneous Omacetaxine (OM) Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients Following Multiple Tyrosine Kinase Inhibitor (TKI) Failure.

Jorge E. Cortes, MD, Meir Wetzler, MD, Jeff Lipton, MD, FRCPC, Franck E. Nicolini, MD, PhD, Michele Baccarani, MD, Maria R. Baer, MD, H. Jean Khoury, David Cram, PharmD, Eric D. Humphriss, BA, Annie-Claude Benichou, MD, Adam Craig, MD, PhD and Hagop M. Kantarjian, MD

Bosutinib as Third-Line Treatment for Chronic Phase Chronic Myeloid Leukemia Following Failure of Second-Line Therapy with Dasatinib or Nilotinib.

H. Jean Khoury, Dong-Wook Kim, MD, Andrey Zaritskey, Carlo Gambacorti-Passerini, Andreas Hochhaus, Juan Navarro, Aaron P. Rapoport, Pedro Enrique Dorlhiac-Llacer, Maria Zanichelli, Virginia Kelly, Nadine Besson, Trevor McMullan, Hagop M. Kantarjian and Jorge E. Cortes

Education Presentations

MicroRNA Maestros of Hematopoiesis.
MD Scientific Program Session: MicroRNAs, and Myeloid Differentiation and Function.

Kara A. Scheibner, PhD, Diane Heiser, Ian M Kaplan, Wen-Chih Cheng, PhD, MinJung Kim, PhD, Shubhada Shashikant Bharne, PhD, Sebastien Morisot, PhD and Curt I. Civin

Dr. Ann Zimrin, "Best Practices Survey," Training Program Directors' Workshop.

Dr. Ann Zimrin, "Hands-On Activity -- Life Is A Crapshoot," High School Student Symposium.

This page was last updated on: October 5, 2011.